MediWound Ltd. (NASDAQ:MDWD) Stock Has Average Target Price of $33.00 According to Analysts

MediWound Ltd. (NASDAQ:MDWD) has received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $33.00.

Several equities research analysts recently issued reports on the company. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Weiss Ratings lowered MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. TD Cowen reaffirmed a “buy” rating on shares of MediWound in a report on Thursday, September 24th. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a research report on Wednesday, September 16th. Finally, Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 26th.

Insider Buying and Selling

In other news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On MediWound

A hedge fund recently raised its position in MediWound stock. Russell Investments Group Ltd. increased its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 750.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,494 shares of the biopharmaceutical company’s stock after purchasing an additional 50,732 shares during the quarter. Russell Investments Group Ltd. owned 0.44% of MediWound worth $792,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Stock Down 1.2%

MediWound stock opened at $14.08 on Thursday. MediWound has a 1-year low of $11.80 and a 1-year high of $19.70. The firm’s 50 day simple moving average is $13.16 and its 200 day simple moving average is $15.14.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. As a group, analysts predict that MediWound will post -2.37 earnings per share for the current year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.